GeninCode partnered with Thermo Fisher Scientific to manufacture, distribute and sell its Cardio InCode-Score, an in vitro polygenic risk score (PRS) test for cardiovascular disease, across the US, Europe, Middle East and Africa. The assay was developed on Thermo Fisher’s QuantStudio 5 Dx platform; GeninCode said the arrangement will support broader market access following New York State approval and an expected FDA de novo submission next quarter. Separately, Devyser received Health Canada approval for its One Lambda Devyser Chimerism NGS test and companion Advyser Chimerism analysis software to monitor donor vs recipient DNA after hematopoietic stem cell transplantation. Thermo Fisher retains exclusive North American and European commercialization rights for the Devyser test, reflecting continued diagnostics consolidation between assay innovators and global lab platform vendors.